JH-RE-06 is a Potent REV1-REV7 Interface Inhibitor for Chemotherapy Improvement
DNA-damaging chemotherapeutics, such as Cisplatin, have been the mainstay of cancer treatment for decades. These therapies generate DNA lesions, and high-fidelity replicative DNA polymerases as the template cannot utilization. Thus, it blocks the progression of the replication fork, generates cytotoxicity, and ultimately causes cell death. However, cells employ specialized...